Journal of Internal Medicine 1996; **240**: 407–410

Author index

Åberg A *see* Agardh *et al.*
Aboderin I, Venables G. Stroke management in Europe (Consensus report) 173
Adams HP Jr. The importance of the Helsingborg Declaration on stroke management in Europe (Editorial) 169
Agardh C-D, Åberg A, Nordén NE. Glucose levels and insulin secretion during a 75g glucose challenge test in normal pregnancy 303
Agger AO *see* Milman *et al.*
Aho H *see* Kotilainen *et al.*
Aho K *see* Kaipiainen-Seppänen
Aimone-Gastin I *see* Bellou *et al.*
Allander T *see* Persson
Aller A, Lorente L, Arias JL, Arias J. Atherosclerosis and expression of the neuro-immune-endocrine system (Letter to the Editor) 50
Andersson C *see* Blom *et al.*
Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria 195
Andersson SA, Hjermann I, Urdal P, Torjesen PA, Holme I. Improved carbohydrate metabolism after physical training and dietary intervention in individuals with the 'atherothrombogenic syndrome'. Oslo Diet and Exercise Study (ODES). A randomized trial 203
Arias J *see* Aller *et al.*
Arias JL *see* Aller *et al.*
Asola M *see* Kotilainen *et al.*
Asplund K *see* Stegmayr

Ballaré M *see* Bordin *et al.*
Balson KR, Niall JF, Best JD. Glomerular lipid deposition and proteinuria in a patient with familial dysbetalipoproteinaemia (Case report) 157
Barilli L *see* Zavaroni *et al.*
Bastion Y *see* Zenone *et al.*
Belch JJ *see* Verstraete *et al.*
Bellou A, Aimone-Gastin I, De Korwin J-D, Bronowicki J-P, Moneret-Vautrin A, Nicolas J-P, Bigard M-A, Guéant J-L. Cobalamin deficiency with megaloblastic anaemia in one patient under long-term omeprazole therapy (Case report) 161
Bendz H, Sjödin I, Toss G, Berglund K. Hyperparathyroidism and long-term lithium therapy – a cross-sectional study and the effect of lithium withdrawal 357
Bergenheim T *see* Borssén *et al.*
Berglund K *see* Bendz *et al.*
Bergqvist D. Low molecular weight heparins (Review) 63
Bernard JP *see* Zenone *et al.*
Best JD *see* Balson *et al.*
Bigard M-A *see* Bellou *et al.*
Bird AG *see* Sewell *et al.*
Bjerle P *see* Blom *et al.*
Bjersing L *see* Andersson *et al.*
Bjerve KS *see* Carlsen *et al.*
Blom H, Andersson C, Olofsson B-O, Bjerle P, Wiklund U, Lithner F. Assessment of autonomic nerve function in acute intermittent porphyria; a study based on spectral analysis of heart rate variability 73
Boldorini R *see* Bordin *et al.*
Bonini L *see* Zavaroni *et al.*
Borch-Iohnsen B *see* Sandstad
Bordin G, Ballaré M, Paglino S, Ravanini P, Dulio D, Malosso MC, Boldorini R, Monteverde A. Idiopathic CD4+lymphocytopenia and systemic vasculitis (Case report) 37
Borgquist L *see* Johannesson *et al.*
Borssén B, Bergenheim T, Lithner F. Preventive treatment of foot deformities in Type 1 diabetic patients aged 15–50 years – an epidemiological and prospective study 219
Bronowicki J-P *see* Bellou *et al.*
Bryon PA *see* Zenone *et al.*
Bugge JF. Severe hyperkalaemia induced by trimethoprim in combination with an angiotensin-converting enzyme inhibitor in a patient with transplanted lungs (Case report) 249

Carlsen SM, Rossvoll O, Bjerve KS, Følling I. Reply to: Hoogeveen & Stehouwer. Should metformin be used to improve blood lipid pattern in nondiabetic patients with coronary heart disease? (Letter to the Editor) 47
Çelik İ *see* Haznedaroğlu *et al.*
Chantelau E. Screening for diabetic retinopathy (Letter to the Editor) 45
Cheng H-M. Lipoproteins, anticardiolipin autoantibodies and atherosclerosis (Letter to the Editor) 44
Christensen K, Vaupel JW. Determinants of longevity: genetic, environmental and medical factors (Review) 333
Ciafre S *see* Napoli *et al.*
Cioni F *see* Zavaroni *et al.*
Coiffier B *see* Zenone *et al.*
Cunningham-Rundles C *see* Zenone *et al.*

Dahl ML *see* Gustafsson *et al.*
Dahlander B, Odeberg H, Hansen BU. Polyarteritis nodosa: ischaemic intestinal pain successfully treated with nitroglycerin (Case report) 31
Dahlén G *see* Wållberg-Jonsson *et al.*
Dall'Aglio E *see* Zavaroni *et al.*
Damsgaard EM *see* Vestbo *et al.*
d'Armiento FP *see* Napoli *et al.*
Dash C *see* Lindholm *et al.*
De Korwin J-D *see* Bellou *et al.*
di Benedetto A *see* Napoli *et al.*
di Ieso N *see* Napoli *et al.*
Dormandy JA *see* Verstraete *et al.*
Du Buf-Vereijken PWG *see* Van Puijenbroek *et al.*
Dulio D *see* Bordin *et al.*
Dullaart RPF *see* Ligtenberg *et al.*
Dündar SV *see* Haznedaroglu *et al.*

Ekbom T *see* Lindholm *et al.*
Eklund A, Grunewald J. The riddle of sarcoidosis: have novel techniques brought any new insights as to the causative agent? (Editorial) 59
Eleborg L *see* Gustafsson *et al.*
Engel A *see* Finkelstein *et al.*
Ericzon BG *see* Gustafsson *et al.*

© 1996 Blackwell Science Ltd

Eriksson LS *see* Gustafsson *et al.*
Espinouse D *see* Zenone *et al.*

Fagerström K-O *see* Nilsson *et al.*
Falk P. *Helicobacter pylori* – can the mechanisms of pathogenesis guide us towards novel strategies for treatment and prevention? (Review) 319
Fellström B. Transplantation atherosclerosis (Editorial) 253
Felman P *see* Zenone *et al.*
Ferguson A. New perspectives of the pathogenesis of coeliac disease: evolution of a working clinical definition (Editorial) 315
Fernqvist-Forbes E *see* Wahren *et al.*
Fernström A, Hylander B, Rössner S. Energy intake in patients on continuous ambulatory peritoneal dialysis and haemodialysis 211
Finkelstein R *see* Levy *et al.*
Finkelstein R, Engel A, Simri W, Hemli JA. Brain abscesses: the lung connection (Case report) 33
Følling I *see* Carlsen *et al.*
Frøland A *see* Vestbo *et al.*

Galløe A *see* Milman *et al.*
Gasparini P *see* Zavaroni *et al.*
Grankvist S *see* Luomanmäki *et al.*
Graudal N *see* Milman *et al.*
Grunewald J *see* Eklund
Guéant J-L *see* Bellou *et al.*
Gustafsson LL, Eriksson LS, Dahl ML, Eleborg L, Ericzon BG, Nyberg A. Cyclophosphamide-induced acute liver failure requiring transplantation in a patient with genetically deficient debrisoquine metabolism: a causal relationship? (Case report) 311

Hallert C *see* Luomanmäki *et al.*
Hansen BU *see* Dahlander *et al.*
Hansson GK *see* Yokota
Harvald B. Reply to: Uzych. Making doctors change (Letter to the Editor) 52
Hayek T *see* Levy *et al.*
Haznedaroğlu İC, Özcebe Oİ, Özdemir O, Çelik İ, Dündar SV, Kirazli Ş. Impaired haemostatic kinetics and endothelial function in Behçet's disease 181
Heikkilä J *see* Kotamäki *et al.*
Hemli JA *see* Finkelstein *et al.*
Hjermann I *see* Andersson *et al.*
Holme I *see* Andersson *et al.*
Holmström M *see* Lindmarker
Hoogeveen EK, Stehouwer CDA. Should metformin be used to improve blood lipid pattern in nondiabetic patients with coronary heart disease? (Letter to the Editor) 46
Hovenier R *see* Urgert *et al.*
Hylander B *see* Fernström *et al.*

Isacsson Å *see* Lindholm *et al.*
Iversen OH *see* Wetteland *et al.*
Iversen OH, Røger M, Solberg HE, Wetteland P. Rising erythrocyte sedimentation rate during several years before diagnosis can be a predictive factor in 70% of renal cell carcinoma patients. The benefit of knowing subject-based reference values 133

Jauro I *see* Luomanmäki *et al.*
Jendle JH, Karlberg BE. Intrapulmonary administration of insulin to healthy volunteers 93
Johannesson M, Borgquist L, Jönsson B, Lindholm LH. The cost effectiveness of lipid lowering in Swedish primary health care 23
Johansson B-L *see* Wahren *et al.*
Johnson O *see* Wållberg-Jonsson *et al.*
Jolobe OMP. 'Calcific degeneration of the aortic valve in old age: is the development of flow obstruction predictable?' (Letter to the Editor) 43
Jönsson B *see* Johannesson *et al.*

Kainulainen L *see* Kotilainen *et al.*
Kaipiainen-Seppänen O, Aho K. Incidence of rare systemic rheumatic and connective tissue diseases in Finland 81
Kalk WJ. Reply to: Chantelau. Screening for diabetic retinopathy (Letter to the Editor) 46
Kang JX *see* Leaf
Kärkkäinen M *see* Silvennoinen *et al.*
Karlberg BE *see* Jendle
Karlberg BE *see* Nyström *et al.*
Katan MB *see* Urgert *et al.*
Ketola K *see* Luomanmäki *et al.*
Kim HC *see* Luomanmäki *et al.*
Kirazli Ş *see* Haznedaroğlu *et al.*
Kiviniemi H *see* Luomanmäki *et al.*
Koskivirta H *see* Luomanmäki *et al.*
Kotamäki M, Laustiola K, Syvänne M, Heikkilä J. Influence of continued smoking and some biological risk factors on restenosis after percutaneous transluminal coronary angioplasty 293
Kotilainen P, Vuori K, Kainulainen L, Aho H, Saario R, Asola M, Nikoskelainen J. Systemic amyloidosis in a patient with hypogammaglobulinaemia (Case report) 103

Lamberg-Allardt C *see* Silvennoinen *et al.*
Laustiola K *see* Kotamäki *et al.*
Lavery LA *see* Van Houtum
Leaf A, Kang JX. Prevention of cardiac sudden death by n-3 fatty acids: a review of the evidence (Review) 5
Lefvert AK, Nityanand S. Reply to: Cheng. Lipoproteins, anticardiolipin autoantibodies and atherosclerosis (Letter to the Editor) 45
Lehtola J *see* Silvennoinen *et al.*
Lernmark Å. Glutamic acid decarboxylase – gene to antigen to disease (Frontiers in medicine) 259
Leu M-L *see* Lin
Levy Y, Hayek T, Finkelstein R. Sarcoidosis mimicking toxoplasmosis with severe hypercalcaemia and normal 1,25-dihydroxy vitamin D (Case report) 165
Ligtenberg JJM, Van Tol A, Van Haeften TW, Sluiter WJ, Reitsma WD, Dullaart RPF. Impaired suppression of plasma free fatty acids and triglycerides by acute hyperglycaemia-induced hyperinsulinaemia and alterations in high density lipoproteins in essential hypertension 233
Liguori A *see* Napoli *et al.*
Lin J-L, Leu M-L. Aluminium-containing agents may be toxic in predialysis chronic renal insufficiency patients 243
Linde B *see* Wahren *et al.*

Lindholm LH *see* Johannesson *et al.*
Lindholm LH, Ekbom T, Dash C, Isacsson Å, Scherstén B. Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main results of the CELL Study 13
Lindmarker P, Holmström M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting 395
Lithner F *see* Andersson *et al.*
Lithner F *see* Blom *et al.*
Lithner F *see* Borssén *et al.*
Lorente L *see* Aller *et al.*
Lundgren H *see* Nilsson *et al.*
Lund-Larsen PG *see* Urgert *et al.*
Luomanmäki K, Grankvist S, Hallert C, Jauro I, Ketola K, Kim HC, Kiviniemi H, Koskivirta H, Sörskog L, Vilkko P. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis 85

Malmström O *see* Nyström *et al.*
Malosso MC *see* Bordin *et al.*
Marshall SEF *see* Sewell *et al.*
Milman N, Graudal N, Galløe A, Agger AO. Reply to: Sandstad & Borch-Iohnsen. Serum ferritin and selective iron prophylaxis in pregnancy? (Letter to the Editor) 48
Mogensen CE *see* Vestbo *et al.*
Moneret-Vautrin A *see* Bellou *et al.*
Monteverde A *see* Bordin *et al.*
Morel D *see* Zenone *et al.*

Napoli C, Liguori A, Sorice P, di Benedetto A, Ciafre S, Posca T, di Ieso N, d'Armiento FP. Relations between vasoactive hormones and diastolic function in hypertensive uraemic patients 389
Niall JF *see* Balson *et al.*
Nicolas J-P *see* Bellou *et al.*
Niemelä S *see* Silvennoinen *et al.*
Nikoskelainen J *see* Kotilainen *et al.*
Nilsson P, Lundgren H, Söderström M, Fagerström K-O, Nilsson-Ehle P. Effects of smoking cessation on insulin and cardiovascular risk factors – a controlled study of 4 months' duration 189
Nilsson-Ehle P *see* Nilsson *et al.*
Nityanand S *see* Lefvert
Nordén NE *see* Agardh *et al.*
Nyberg A *see* Gustafsson *et al.*
Nyström F, Malmström O, Karlberg BE, Öhman KP. Twenty-four hour ambulatory blood pressure in the population 279

Odeberg H *see* Dahlander *et al.*
Öhman KP *see* Nyström *et al.*
Olivecrona G *see* Wållberg-Jonsson *et al.*
Olofsson B-O *see* Blom *et al.*
Özcebe Oİ *see* Haznedaroğlu *et al.*
Özdemir O *see* Haznedaroglu *et al.*

Paglino S *see* Bordin *et al.*
Persson MAA, Allander T. Hepatitis C virus transmission in hospitals (Editorial) 1

Posca T *see* Napoli *et al.*

Rantapää-Dahlqvist S *see* Wållberg-Jonsson *et al.*
Ravanini P *see* Bordin *et al.*
Reaven GM *see* Zavaroni *et al.*
Reitsma WD *see* Ligtenberg *et al.*
Rieux C *see* Zenone *et al.*
Rodés J. Pathogenesis and treatment of ascites (Editorial) 111
Røger M *see* Iversen *et al.*
Røger M *see* Wetteland *et al.*
Rössner S *see* Fernström *et al.*
Rossvoll O *see* Carlsen *et al.*

Saario R *see* Kotilainen *et al.*
Salles G *see* Zenone *et al.*
Sandstad B, Borch-Iohnsen B. Serum ferritin and selective iron prophylaxis in pregnancy? (Letter to the Editor) 47
Scherstén B *see* Lindholm *et al.*
Sewell WAC, Marshall SEF, Bird AG. Systemic lupus erythematosus as a cause of the pulmonary renal syndrome (Letter to the Editor) 43
Silvennoinen J, Lamberg-Allardt C, Kärkkäinen M, Niemelä S, Lehtola J. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease 285
Simri W *see* Finkelstein *et al.*
Sjödin I *see* Bendz *et al.*
Sluiter WJ *see* Ligtenberg *et al.*
Söderström M *see* Nilsson *et al.*
Solberg HE *see* Iversen *et al.*
Solberg HE *see* Wetteland *et al.*
Sorice P *see* Napoli *et al.*
Sörskog L *see* Luomanmäki *et al.*
Souquet PJ *see* Zenone *et al.*
Spooren PFMJ *see* Van Puijenbroek *et al.*
Stegmayr B, Asplund K. Exploring the declining case fatality in acute stroke. Population-based observations in the northern Sweden MONICA Project 143
Stehouwer CDA *see* Hoogeveen
Strata A *see* Zavaroni *et al.*
Syvänne M *see* Kotamäki *et al.*

Torjesen PA *see* Andersson *et al.*
Toss G *see* Bendz *et al.*

Urdal P *see* Andersson *et al.*
Urgert R, Weusten-van der Wouw MPME, Hovenier R, Lund-Larsen PG, Katan MB. Chronic consumers of boiled coffee have elevated serum levels of lipoprotein(a) 367
Uzych L. Making doctors change (Letter to the Editor) 51

Van Doormaal JJ *see* Van Puijenbroek *et al.*
Van Haeften TW *see* Ligtenberg *et al.*
Van Houtum WH, Lavery LA. Outcomes associated with diabetes-related amputations in the Netherlands and in the state of California, USA 227
Van Puijenbroek EP, Du Buf-Vereijken PWG, Spooren PFMJ, Van Doormaal JJ. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil (Case report) 403
Van Tol A *see* Ligtenberg *et al.*
Vaupel JW *see* Christensen

Venables G *see* Aboderin
Verhaeghe R *see* Verstraete *et al.*
Verstraete M, Belch JJ, Dormandy JA, Verhaeghe R. Thrombolysis in the management of limb arterial occlusion. Towards a consensus (Consensus report) 343
Vestbo E, Damsgaard EM, Frøland A, Mogensen CE. Clinical features in persons with a family history of diabetes compared to controls (The Second Generation Fredericia Study) 381
Vilkko P *see* Luomanmäki *et al.*
Vuori K *see* Kotilainen *et al.*

Wahren J, Johansson B-L, Wallberg-Henriksson H, Linde B, Fernqvist-Forbes E, Zierath JR. C-peptide revisited – new physiological effects and therapeutic implications (Frontiers in medicine) 115
Wallberg-Henriksson H *see* Wahren *et al.*
Wållberg-Jonsson S, Dahlén G, Johnson O, Olivecrona G, Rantapää-Dahlqvist S. Lipoprotein lipase in relation to inflammatory activity in rheumatoid arthritis 373
Wetteland P *see* Iversen *et al.*
Wetteland P, Røger M, Solberg HE, Iversen OH. Population-based erythrocyte sedimentation rates in 3910 subjectively healthy Norwegian adults. A statistical study based on men and women from the Oslo area 125
Weusten-van der Wouw MPME *see* Urgert *et al.*
Wiklund U *see* Blom *et al.*

Yokota T, Hansson GK. Reply to: Aller *et al.* Atherosclerosis and expression of the neuro-immune-endocrine system (Letter to the Editor) 51

Zavaroni I, Bonini L, Gasparini P, Zuccarelli A, Dall'Aglio E, Barilli L, Cioni F, Strata A, Reaven GM. Dissociation between urinary albumin excretion and variables associated with insulin resistance in a healthy population 151
Zenone T, Bastion Y, Salles G, Rieux C, Morel D, Felman P, Espinouse D, Bryon PA, Coiffier B. POEMS syndrome, arterial thrombosis and thrombocythaemia (Case report) 107
Zenone T, Souquet PJ, Cunningham-Rundles C, Bernard JP. Hodgkin's disease associated with IgA and IgG subclass deficiency (Case report) 99
Zierath JR *see* Wahren *et al.*
Zuccarelli A *see* Zavaroni *et al.*

Journal of Internal Medicine 1996; 240: 411–414

Subject index

ACE-inhibitors
  trimethoprim-induced hyperkalaemia, 249
Acute intermittent porphyria
  autonomic nerve function, 73
  hepatocellular carcinoma, 195
Adenocarcinoma
  pathogenesis of *Helicobacter pylori*, 319
Adverse effect
  cyclophosphamide-induced liver failure, 311
  use of simvastatin and gemfibrozil, 403
Aerosols
  intrapulmonary insulin, 93
Ageing
  calcific degeneration of aortic valve, 43
Al-containing agents
  toxicity in chronic renal insufficiency, 243
Aluminium (Al)
  toxicity in chronic renal insufficiency, 243
Amputation
  diabetes-related, 227
Amyloidosis
  in hypogammaglobulinaemia, 103
Anticardiolipin antibodies
  lipoproteins and atherosclerosis, 44
Aortic valve
  calcific degeneration in elderly people, 43
Arthritis
  hypogammaglobulinaemia-associated amyloidosis, 103
  lipoprotein lipase in rheumatoid arthritis, 373
Ascites
  pathogenesis and treatment, 111
Asymptomatic individuals
  erythrocyte sedimentation rates, 125
Atherosclerosis
  expression of neuro-immune-endocrine system, 50
  lipoproteins and anticardiolipin antibodies, 44
  transplantation, 253
'Atherothrombogenic syndrome'
  lifestyle intervention, 203
Atrial natriuretic factor
  hypertensive uraemic patients, 389
Autonomic nervous system
  function in acute intermittent porphyria, 73

Behçet's disease
  haemostatic kinetics and endothelial function, 181
Blood pressure
  ambulatory reference data, 279
  free fatty acids and HDL lipids, 233
  microalbuminuria and insulin resistance, 151
Body mass index
  family history of diabetes, 381
Boiled coffee
  serum levels of lipoprotein(a), 367
Bone mineral density
  calcium intake in inflammatory bowel disease, 285
Brain abscess
  pulmonary A–V fistula, 33

Calcific degeneration of aortic valve
  elderly people, 43
Calcium intake
  bone mineral density in inflammatory bowel disease, 285
Calorie intake
  and dialysis, 211
Cardiac arrhythmias
  acute intermittent porphyria, 73
  prevention by n-3 fatty acids, 5
Cardiolipin
  anticardiolipin antibodies and atherosclerosis, 44
Cardiovascular risk factors
  effects of smoking cessation, 189
  family history of diabetes, 381
  lifestyle intervention and 'atherothrombogenic syndrome', 203
  results of CELL Study, 13
Case fatality
  decline in acute stroke, 143
Centenarians
  determinants of longevity, 333
Cerebrovascular disorders
  declining case fatality in acute stroke, 143
  importance of Helsingborg Declaration, 169
  stroke management in Europe, 173
Cholesterol
  cost effectiveness of lipid lowering, 23
  HDL-cholesterol, microalbuminuria and insulin resistance, 151
  results of CELL Study, 13
Cholesteryl ester transfer protein
  in essential hypertension, 233
Chronic rejection
  transplantation atherosclerosis, 253
Chronic renal insufficiency
  aluminium and iron in patients, 243
Chronic uraemia
  hormones and diastolic function in hypertensive patients, 389
Coagulation
  haemostasis in Behçet's disease, 181
Cobalamin
  deficiency with megaloblastic anaemia in omeprazole therapy, 161
Coeliac disease
  new perspectives on pathogenesis, 315
Connective tissue disease
  rare systemic diseases in Finland, 81
Coronary heart disease
  metformin in nondiabetic patients, 46
Cost containment
  making doctors change, 51
Cost effectiveness
  lipid lowering, 23
Cost-minimization
  dalteparin for treatment of deep vein thrombosis, 395
C-peptide
  intrapulmonary insulin, 93

© 1996 Blackwell Science Ltd

physiological effects, 115
smoking cessation and risk factors, 189
Crohn's disease
calcium intake and bone mineral density, 285
Cyclophosphamide
liver failure and debrisoquine metabolism, 311

Dalteparin
treatment of deep vein thrombosis, 85, 395
Debrisoquine
cyclophosphamide-induced liver failure, 311
Deep vein thrombosis (DVT)
dalteparin in an outpatient setting, 395
low molecular weight heparins, 63
once-daily subcutaneous dalteparin, 85
Diabetes
clinical features in persons with a family history, 381
C-peptide in insulin-dependent (IDDM) patients, 115
outcomes associated with amputations, 227
prevention of foot deformities, 219
screening for retinopathy, 45
Diastolic function
hypertensive uraemic patients, 389
Diet
calcium intake in inflammatory bowel disease, 285
energy intake and dialysis, 211
lifestyle intervention and 'atherothrombogenic syndrome', 203
1,25-dihydroxy vitamin D
normal levels in sarcoidosis with hypercalcaemia, 165
Disease-predictive power of ESR
population-based reference values, 125
renal cell carcinoma and early elevation, 133
Diurnal rhythm
ambulatory blood pressure, 279
Doctors
making them change, 51
Drug treatment
cost effectiveness of lipid lowering, 23
Dyslipidaemia
familial dysbetalipoproteinaemia, 157

Economic evaluation
lipid lowering, 23
Endothelin
ET-1 in hypertensive uraemic patients, 389
risk factors and restenosis, 293
Epidemiology
diabetes-related amputations, 227
hepatocellular carcinoma in acute intermittent porphyria, 195
hyperparathyroidism and long-term lithium therapy, 357
rare systemic diseases in Finland, 81
Erythrocyte sedimentation rate (ESR)
population-based reference values, 125
renal cell carcinoma and early elevation, 133
Evaluation of effectiveness of intervention
stroke management in Europe, 173
Exercise
lifestyle intervention and 'atherothrombogenic syndrome', 203
Extremity
diabetes-related amputation, 227

Ferritin
aluminium and iron in chronic renal insufficiency, 243
selective iron prophylaxis in pregnancy, 47
Fibrinogen
smoking cessation and risk factors, 189
Fibrinolysis
haemostasis in Behçet's disease, 181
Foot
diabetes-related amputation, 227
prevention of deformities in diabetes, 219
Free fatty acids
in essential hypertension, 233

GABA (gamma-aminobutyric acid)
glutamic acid decarboxylase, 259
Gemfibrozil
and simvastatin, risk of rhabdomyolysis, 403
Genotype
deficient debrisoquine metabolism, 311
Glomerular hyperfiltration
effects of C-peptide in IDDM, 115
Glucose
lifestyle intervention and 'atherothrombogenic syndrome', 203
metabolism during normal pregnancy, 303
microalbuminuria and insulin resistance, 151
smoking cessation and risk factors, 189
uptake and effects of C-peptide in IDDM, 115
Glutamic acid decarboxylase (GAD)
gene to antigen to disease, 259

Haemodialysis
energy intake, 211
low molecular weight heparins, 63
Haemostasis
impairment in Behçet's disease, 181
Heart rate variability
spectral analysis in acute intermittent porphyria, 73
Helicobacter pylori
pathogenesis and novel strategies, 319
Hepatitis C virus
transmission in hospitals, 1
Hepatocellular carcinoma
in acute intermittent porphyria, 195
High-density lipoprotein (HDL)-cholesterol
microalbuminuria and insulin resistance, 151
Hodgkin's disease
IgA and IgG subclass deficiency, 99
Hospitals
transmission of hepatitis C virus, 1
Hypercalcaemia
long-term lithium therapy, 357
sarcoidosis and toxoplasmosis, 165
Hyperkalaemia
trimethoprim-induced, 249
Hyperparathyroidism
long-term lithium therapy, 357
Hypertension *see* Blood pressure
Hypogammaglobulinaemia
and systemic amyloidosis, 103

Idiopathic CD4 lymphocytopenia
systemic vasculitis, 37
Immunoglobulin deficiency
amyloidosis in hypogammaglobulinaemia, 103
Hodgkin's disease, 99
Immunosuppression
idiopathic CD4 lymphocytopenia, 37
Incidence
rare systemic diseases in Finland, 81
Infection
pathogenesis of *Helicobacter pylori*, 319
Inflammation
lipoprotein lipase and rheumatoid arthritis, 373
pathogenesis of *Helicobacter pylori*, 319
Inflammatory bowel disease
calcium intake and bone mineral density, 285
Insulin
effects of smoking cessation, 189
free fatty acids and HDL lipids in hypertension, 233
intrapulmonary administration, 93
lifestyle intervention and 'atherothrombogenic syndrome', 203
microalbuminuria and variables associated with resistance, 151
Insulin secretion
effects of C-peptide, 115
glucose tolerance in normal pregnancy, 303
Iron
aluminium toxicity in chronic renal insufficiency, 243
serum ferritin and prophylaxis in pregnancy, 47
Ischaemic pain
nitroglycerin in polyarteritis nodosa, 31

LDL receptor-related protein
lipoprotein lipase and rheumatoid arthritis, 373
Lecithin:cholesterol acyltransferase
in essential hypertension, 233
Life expectancy
determinants of longevity, 333
Limb arterial occlusion
thrombolytic therapy, 343
Lipid load
inflammatory activity in rheumatoid arthritis, 373
Lipid-lowering medication
metformin, 46
results of CELL Study, 13
Lipoprotein lipase mass
inflammatory activity in rheumatoid arthritis, 373
Lipoproteins
anticardiolipin autoantibodies and atherosclerosis, 44
boiled coffee and serum levels of lipoprotein(a), 367
in essential hypertension, 233
familial dysbetalipoproteinaemia, 157
HDL-cholesterol, microalbuminuria and insulin resistance, 151
smoking cessation and risk factors, 189
Lithium toxicity
hyperparathyroidism and long-term therapy, 357
Liver cirrhosis
hepatocellular carcinoma in acute intermittent porphyria, 195
Liver failure
cyclophosphamide-induced, and debrisoquine metabolism, 311
Low molecular weight heparins (LMWH), 63
dalteparin in treatment of deep vein thrombosis, 85, 395

Malabsorption
cobalamin deficiency in omeprazole therapy, 161
Marder score
treatment of deep vein thrombosis, 85
Megaloblastic anaemia
cobalamin deficiency in omeprazole therapy, 161
Metabolism
debrisoquine, genetically deficient, 311
Metformin
nondiabetic patients with coronary heart disease, 46
Microalbuminuria
effects of C-peptide in IDDM, 115
and insulin resistance, 151
Microcirculation
effects of C-peptide in IDDM, 115
Mortality
determinants of longevity, 333
Moulded insoles
prevention of diabetic foot deformities, 219

N-3 fatty acids
prevention of cardiac sudden death, 5
N-6 fatty acids
prevention of cardiac sudden death, 5
Na+,K+-ATPase
effects of C-peptide, 115
Nebulization
intrapulmonary insulin, 93
Neuro-immune-endocrine system
atherosclerosis, 50
Neuropathy
effects of C-peptide in IDDM, 115
prevention of diabetic foot deformities, 219
Nitroglycerin
ischaemic pain in polyarteritis nodosa, 31
Non-insulin dependent diabetes mellitus (NIDDM)
clinical features in persons with a family history, 381
Nonpharmacological treatment
cardiovascular risk factors, 13
cost effectiveness of lipid lowering, 23
Norwegians
consumers of boiled coffee, 367

Omeprazole
cobalamin deficiency with megaloblastic anaemia, 161
Opportunistic infection
idiopathic CD4 lymphocytopenia, 37
Oral inhalation
intrapulmonary insulin, 93
Osteoporosis
calcium intake in inflammatory bowel disease, 285
Oxidative stress
hepatocellular carcinoma in acute intermittent porphyria, 195

Pathogenesis
ascites, 111

coeliac disease, 315
Helicobacter pylori, 319
hepatocellular carcinoma in acute intermittent porphyria, 195
Percutaneous transluminal coronary angioplasty
risk factors and restenosis, 293
Periarteritis nodosa
ischaemic pain and nitroglycerin, 31
Peritoneal dialysis
energy intake, 211
POEMS syndrome
arterial thrombosis and thrombocythaemia, 107
Polyunsaturated fatty acids
prevention of cardiac sudden death, 5
Postoperative complications
low molecular weight heparins, 63
Pregnancy
glucose levels and insulin secretion, 303
serum ferritin and iron prophylaxis, 47
Prevention of arrhythmias
n-3 fatty acids, 5
Proteinuria
familial dysbetalipoproteinaemia, 157
Pulmonary A–V fistula
brain abscess, 33
Pulmonary embolism
low molecular weight heparins, 63
Pulmonary renal syndrome
systemic lupus erythematosus as cause, 43

Reference values
ambulatory blood pressure, 279
erythrocyte sedimentation rate, 125
Rehabilitation in stroke
management in Europe, 173
Renal disease
aluminium in chronic renal insufficiency patients, 243
familial dysbetalipoproteinaemia, 157
renal cell carcinoma (RCC) and early elevating ESR, 133
Renal function
hyperparathyroidism and long-term lithium therapy, 357
Rendu–Osler–Weber disease
brain abscess, 33
Restenosis
risk factors after percutaneous transluminal coronary angioplasty, 293
Retinopathy
screening in diabetes, 45
Rhabdomyolysis
use of simvastatin and gemfibrozil, 403
Rheumatoid arthritis
lipoprotein lipase and inflammatory activity, 373

Sarcoidosis
mimicking toxoplasmosis, 165
novel techniques and new insights, 59
Simvastatin
and gemfibrozil, risk of rhabdomyolysis, 403
Smoking
cessation and risk factors, 189
restenosis after percutaneous transluminal coronary angioplasty, 293
Spectral analysis
heart rate variability in acute intermittent porphyria, 73
Stroke
declining case fatality in acute stroke, 143
importance of Helsingborg Declaration, 169
management in Europe, 173
Systemic lupus erythematosus
pulmonary renal syndrome, 43

Thrombocythaemia
POEMS syndrome and arterial thrombosis, 107
Thrombolysis
management of limb arterial occlusion, 343
Thrombosis
POEMS syndrome and thrombocythaemia, 107
Time factors
ambulatory blood pressure, 279
Time trends
declining case fatality in acute stroke, 143
Toxoplasmosis
and sarcoidosis, 165
Transplantation
atherosclerosis, 253
cyclophosphamide-induced liver failure, 311
Triglycerides
in essential hypertension, 233
microalbuminuria and insulin resistance, 151
Trimethoprim
ACE inhibitors, and hyperkalaemia, 249

Ulcerative colitis
calcium intake and bone mineral density, 285
Unfractionated heparin (UFH)
treatment of deep vein thrombosis, 85

Vasculitis
idiopathic CD4 lymphocytopenia, 37
polyarteritis nodosa and ischaemic pain, 31
rare systemic diseases in Finland, 81
Venography
treatment of deep vein thrombosis, 85
Ventricular fibrillation
prevention by n-3 fatty acids, 5
Vitamin B12
cobalamin deficiency in omeprazole therapy, 161

White coat hypertension
ambulatory blood pressure reference data, 279